Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
186.16
+0.99 (0.53%)
Jan 29, 2026, 9:51 AM EST - Market open
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $170.99M in the quarter ending September 30, 2025, with 63.22% growth. This brings the company's revenue in the last twelve months to $561.26M, up 65.83% year-over-year. In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth.
Revenue (ttm)
$561.26M
Revenue Growth
+65.83%
P/S Ratio
16.24
Revenue / Employee
$687,822
Employees
816
Market Cap
9.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
| Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
| Dec 31, 2022 | 50.04M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.16B |
| BioMarin Pharmaceutical | 3.09B |
| Halozyme Therapeutics | 1.24B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 829.45M |
| Krystal Biotech | 373.16M |
| Cytokinetics | 87.21M |
| Avidity Biosciences | 20.87M |
AXSM News
- 2 days ago - Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 - GlobeNewsWire
- 5 days ago - Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline - Seeking Alpha
- 16 days ago - MoneyShow's Best Investment Ideas For 2026: Part 2 - Seeking Alpha
- 17 days ago - Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue - GlobeNewsWire
- 4 weeks ago - FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars - Benzinga
- 4 weeks ago - Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission - GlobeNewsWire
- 7 weeks ago - Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire